Our generic medicines

From cholesterol reducers and antibiotics to anti infectives and pain relievers

Our speciality medicines

Focusing on MS, cancer, asthma, pain, migraine and more

Research and development

Bringing hope to patients and choice for healthcare professionals

Our generic medicines and key therapy areas

At a global level, Teva has one of the broadest medicines pipelines in the industry, and in the UK Teva is one of the largest suppliers of medicines to the NHS.¹

That means we can be in a strong position to bring generic versions of branded medicines to market on the first day of patent protection ending. Generic medicines are typically sold at a substantially lower price to their branded medicine counterparts, as the development process is generally less costly.

Generic medicines bring significant savings to the NHS medicines bill – estimates are that generic medicines save the NHS over £13 billion every year, compared to the cost if their branded equivalents had been dispensed. This frees up valuable NHS budgets.

View our range of medicines

Generic medicines

Generic medicines save the NHS billions of pounds a year. (2)

Over-the-counter

Our over-the-counter products include a range of consumer healthcare treatments available without a prescription. It also features well-known brands such as Sudocrem® and Infacol®.

Central nervous system (CNS)

We focus on delivering solutions to patients and healthcare professionals via medicines, devices and services for central nervous system (CNS) disorders with a strong emphasis on multiple sclerosis and other neurodegenerative disorders. Within Teva’s CNS medicines are Copaxone® (glatiramer acetate) pre-filled syringe which is for the treatment of multiple sclerosis, and Azilect® (rasagiline) tablets for the treatment of the symptoms of Parkinson’s disease.

Respiratory

Our range of respiratory medicines includes treatments for asthma, severe asthma, COPD and Cystic Fibrosis. Our work focuses on understanding and improving outcomes for patients affected by a respiratory disorder, which also helps the NHS manage its resources. Within our range of inhalers we have a multi-dose dry-powder inhaler for the management of asthma and COPD, and several inhaler devices including a metered dose inhaler for the management of asthma.

Migraine

Oncology

We work hard to ease the way for people with cancer throughout their therapeutic journey and to offer choice and factual scientific based information to Oncology specialists. Our medicines treat cancer and associated conditions like neutropenia and breakthrough cancer pain.

References:

[1] Teva UK data on file
[2] 'NHS costs to soar as drugs become more complex’ – The Times.
http://www.thetimes.co.uk/tto/health/news/article4570428. Last accessed 18.03.16

Teva Ref: HC606